Defining the impact of adjuvant therapy in molecularly defined subsets of gastrointestinal stromal tumor: From lumping to splitting

Michael C. Heinrich; Christopher L. Corless; George D. Demetri

doi:10.1001/jamaoncol.2016.5740

Defining the impact of adjuvant therapy in molecularly defined subsets of gastrointestinal stromal tumor: From lumping to splitting

Michael C. Heinrich, Christopher L. Corless, George D. Demetri

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	597-599
Number of pages	3
Journal	JAMA Oncology
Volume	3
Issue number	5
DOIs	https://doi.org/10.1001/jamaoncol.2016.5740
State	Published - May 1 2017

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2016.5740

Cite this

@article{77844de9977344bd8d30118681aff7b9,

title = "Defining the impact of adjuvant therapy in molecularly defined subsets of gastrointestinal stromal tumor: From lumping to splitting",

author = "Heinrich, {Michael C.} and Corless, {Christopher L.} and Demetri, {George D.}",

note = "Funding Information: Dr Heinrich is a consultant to Molecular MD, Novartis, Pfizer, and Blueprint Medicines; has received speakers honorarium from Novartis and Pfizer; holds equity interest in Molecular MD (nonpublic); has received research funding from Blueprint Medicines, Deciphera Pharmaceuticals, and Inhibikase; holds intellectual property in the form of a patent licensed to Novartis (royalty to Oregon Health and Science University Knight Cancer Institute); and has provided expert testimony (patent litigation) for Novartis. Dr Demetri is a consultant for Novartis, Pfizer, Daiichi-Sankyo, Blueprint Medicines, Kolltan Pharmaceuticals, and Caris Life Sciences; holds equity interest in Blueprint Medicines (public), Kolltan Pharmaceuticals (private), and Caris Life Sciences (public); has received research funding from Novartis, Bayer, and Pfizer; holds intellectual property in the form of a patent licensed to Novartis (royalty to Dana-Farber Cancer Institute); scientific advisory board member for Blueprint Medicines; and board of directors for Blueprint Medicines. No other disclosures are reported. This work was supported in part by funding from the V Foundation for Cancer Research (Dr Heinrich), VA Merit Review Grant 2I01BX000338-05 (Dr Heinrich), GIST Cancer Research Fund (Drs Heinrich and Corless), Life Raft Group (Drs Heinrich and Corless), Ludwig Center at Harvard (Dr Demetri), the Pan Mass Challenge from Paul's Posse and Erica's Entourage (Dr Demetri), the Russo Family Fund for GIST Research (Dr Demetri), and SPORE Grant 1P50CA127003-05 for Gastrointestinal Cancers at Dana-Farber Cancer Institute from the US National Cancer Institute (Dr Demetri).",

year = "2017",

month = may,

day = "1",

doi = "10.1001/jamaoncol.2016.5740",

language = "English (US)",

volume = "3",

pages = "597--599",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "5",

}

TY - JOUR

T1 - Defining the impact of adjuvant therapy in molecularly defined subsets of gastrointestinal stromal tumor

T2 - From lumping to splitting

AU - Heinrich, Michael C.

AU - Corless, Christopher L.

AU - Demetri, George D.

N1 - Funding Information: Dr Heinrich is a consultant to Molecular MD, Novartis, Pfizer, and Blueprint Medicines; has received speakers honorarium from Novartis and Pfizer; holds equity interest in Molecular MD (nonpublic); has received research funding from Blueprint Medicines, Deciphera Pharmaceuticals, and Inhibikase; holds intellectual property in the form of a patent licensed to Novartis (royalty to Oregon Health and Science University Knight Cancer Institute); and has provided expert testimony (patent litigation) for Novartis. Dr Demetri is a consultant for Novartis, Pfizer, Daiichi-Sankyo, Blueprint Medicines, Kolltan Pharmaceuticals, and Caris Life Sciences; holds equity interest in Blueprint Medicines (public), Kolltan Pharmaceuticals (private), and Caris Life Sciences (public); has received research funding from Novartis, Bayer, and Pfizer; holds intellectual property in the form of a patent licensed to Novartis (royalty to Dana-Farber Cancer Institute); scientific advisory board member for Blueprint Medicines; and board of directors for Blueprint Medicines. No other disclosures are reported. This work was supported in part by funding from the V Foundation for Cancer Research (Dr Heinrich), VA Merit Review Grant 2I01BX000338-05 (Dr Heinrich), GIST Cancer Research Fund (Drs Heinrich and Corless), Life Raft Group (Drs Heinrich and Corless), Ludwig Center at Harvard (Dr Demetri), the Pan Mass Challenge from Paul's Posse and Erica's Entourage (Dr Demetri), the Russo Family Fund for GIST Research (Dr Demetri), and SPORE Grant 1P50CA127003-05 for Gastrointestinal Cancers at Dana-Farber Cancer Institute from the US National Cancer Institute (Dr Demetri).

PY - 2017/5/1

Y1 - 2017/5/1

UR - http://www.scopus.com/inward/record.url?scp=85020101481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020101481&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2016.5740

DO - 10.1001/jamaoncol.2016.5740

M3 - Editorial

C2 - 28334361

AN - SCOPUS:85020101481

SN - 2374-2437

VL - 3

SP - 597

EP - 599

JO - JAMA Oncology

JF - JAMA Oncology

IS - 5

ER -

Defining the impact of adjuvant therapy in molecularly defined subsets of gastrointestinal stromal tumor: From lumping to splitting

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this